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Resveratrol Modulation of Microglial Activation and Provision for Neuroprotection
in Multiple Sclerosis
Joseph L. Green

Abstract
Multiple sclerosis (MS) is an autoimmune disease affecting over 2.5 million people
worldwide. In MS, myelin sheaths surround ing the axons of neurons are attacked by the
immune system , leading to many deleterious symptoms. No cure forMS has been found ,
but some treatments reducing the number of exacerbations are available. Studies on
resveratrol show the compound to have anti-inflammatory properties that cou ld be
bencticial in the treatment of diseases like MS. In our research, we used a cellular model
to imitate neurons of the central nervous system and tested the effects of resveratrol in the
hope of finding neuroprotective properties.

Introduction

MS
Multiple Sclerosis affects approximate ly 350,000 people in the United States, 2.5
million people worldwide, and is the most prevalent neurological cause of disabi lity in
young adults (Pinkston, Kablinger et al. 2007). MS occurs more frequently in females
than in males and is more prevalent in some countries than in others (Poser 1994). Even
though research has led to advancements that are minimizing the many mysteries of this
disease, its cause is unknown and a cure is sti ll not avai lable.
MS is an autoimmune disease in which an inflammatory response of unknown
origin causes the immune system to begin a seri es of attacks on the central nervous
system, leading to loss of oligodendrocytes, cells that function to create and maintain the

myelin sheath surroundin g the axons of nerve cells (McQualter and Bernard 2007). The
loss of these cells results in demyelination and axonal degeneration and the formation of
demyelinated lesions because there are an insufficient number of the cells to completely
remyelinate the axons of the nerve cells (Wolswijk 2000). These demyelinated lesions
decrease the efficacy of the electri cal signal that is passed from the nerve cells, a decrease
that is thought to elicit the symptoms normally seen in MS: paralysis, sensory loss,
fatigue, depression, movement problems, tremors, weakness in arms or legs, loss of
balance, and many cognitive defects (McQualter and Bernard 2007).
The lesions in the white matter of the brain characteri stic of MS arc a result of a
defective blood brain barrier, which, when functioning properly. controls entry of certain
molecules into the brain (Dutta and Trapp 2007). In MS, the blood brain barrier allows
certain MITC class-ll positive cells to pass through its tight junctions, resulting in the
arrival of a type of white blood cell called T cells that attack the brain parenchyma.
causing the neurological damage associated with MS (Sospedra and Martin 2005). The
damage done to the axons characteristic toMS is believed to occur secondari ly to the
1

inflammation response. CD4+T cells, CD8 T cells, macrophages, and glial cel ls are
normally responsible for the secretion of cytokincs, chemokines, and other proteins that
mediate the inflammatory response (Taoufik. Tseveleki et al. 2008).
The major histocompatibility complex (MHC) is a group of genes that code for
human lymphocyte antigens (HLA) that line the surface of all nucleated cells. The HLA
proteins arc responsible for the immune system's recognition of"self ' and non-self."
rhcrelorc, a defect in the I ILA system can result in an autoimmune disease. B cells and
macrophages are examples ofthe anti gen-presenting cells belonging to the MHC class- 11
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positive ce ll s. These MHC class-Il complexes are recogni zed by specific mature helper T
cell s that express the surface protein CD4, called CD4+T cells. CD4+ T ce lls release
cytokines that signal other immune cells, therefore amplify ing the immune response
(Cresswell 1998).
The innammatory response in MS is tri ggered when the MHC Class-ll positive
ce ll s that have passed through the blood brain barrier come in contact with an anti gen
present on microglia or astrocytes. This contact initiates the release of many types of
proinflammatory molecul es such as chemokines and cytokines that decrease the
permeability of the blood brain barrier. allowing immune cell s to enter. The regulatory
1

CD4 T ce ll s, along with triggering the inflammatory response, may also aid in the
reduction of oligendrocytes and axonal degeneration (McQualter and Bernard 2007).
The different lesions frequently observed in MS can be divided into three types.
One type, acti ve lesions. contain a high number of MHC Class-II positive ce lls and are
general ly newly formed lesions approx imately a few months old. The cells fo und in
these lesions are macrophages fill ed with lipids, mostly cholesterol. The diffe rence
between this type of lesion and the second type, chronic active lesions, is the myelin
remains left by the macrophages located at the edge of the chronic active lesions. The
third type, chronic inacti ve lesions, is di stinguished by its low number ofM IJC Class-II
pos iti ve ce ll s in compari son to the two other types of lesions. T he les ions with the higher
numbers o f Ml IC Class-II positi ve cell s amplify the inflammator; response, leading to an
increased amount of ti ssue damage (Dutta and Trapp 2007).
MS is characterized by impairment of autonomic, motor, and neurocognitive
function, but the severity of the im pairments varies in individuals suffering from the
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disease ((Sospedra and Martin 2005). Losses of cognitive function occur in about 70
percent of patients with examples such as long-term memory loss, inability to maintain
attenti on. and slower time in processing information (Simioni, Ruffieux et al. 2007).
Though MS does not necessarily shorten the life of an individual suffering from it, the
possible deleterious symptoms can arise without warning and make normal life difficult.
Individuals with multiple sc lerosis experience different symptoms depending on the
nerves affected by active areas of inflammation (Sospedra and Martin 2005).
Giving a prognosis to an individual with MS is very difficult because MS can
remain dormant for a long period of time or progress at a fast pace. The different types
of MS are categorized depending on number, severity. and occurrence of attacks on the
central nervous system. After a single attack, an individual would be diagnosed with a
clinically isolated syndrome. Approximately 85 percent of people with MS suffer from
the relapsing-remitting form in which the central nervous system is attacked without
warning and symptoms are present, but is followed by a period free of attacks. The
damage inflicted as a result of these attacks could lead to permanent symptoms, but other
symptoms are relieved after the attacks cease. Most people suffering from the relapsingremitting type of MS de,·elop the secondary progressive form of MS. In secondary
progressive MS. the patient experiences a worsening of symptoms with no clear absence
of the attacks associated with the disease. Some individuals with this type do experience
a period of remission. Patients that never experience a remission after their first sign of
symptoms and show a progressive worsening of symptoms suffer from primary
progressive MS, which is common in people diagnosed with MS later in life. Those
individuals with progressive MS that suffer another relapse are then categorized as
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having progressive-relapsing MS, which is diagnosed less frequently than the other types.
The factors that trigger the relapses are still unknown, but studies have shown several
factors such as the common cold, influenza, and emotional or physical stress can possibly
contribute to the unpredictable attacks (Murray 2006).

Etiology ofMS
Despite the amount of research on the disease, the exact cause of the
inflammatory response and autoimmune attack in MS is

unkno~11.

Several theories have

been proposed, but none has presented enough evidence to solve this mystery.
Genetic factors have been theorized to be a cause of MS , but the research has
been unsuccessful in finding definitive parallels in the genomes of individuals with the
disease. There have been substantial findings that suggest genetic does play a role in
susceptibility to MS. One such finding shows increased susceptibility to the disease for
persons ofNorth European descent. This study compared ethnic groups living in the
same area. Other findings show an increased risk in close relatives of individuals
suffering from MS; they are up to 40 times more likely to have the disease. Also, an
identical twin of a person with multiple sclerosis is approximately 30 percent more
inclined to get the disease than a fraternal twin, which only has around a seven percent
chance. Researchers believe the mode of inheritance is likely through genes on multiple
loci each contributing to the risks associated with multiple sclerosis (Haines, Terwedow
et al. 1998).
ot all gene-association studies are in agreement about which genes play a vital
role in multiple sclerosis. The genetic region coding for the HLA system has been found
by many genetic linkage studies to be one ofthe contributors to the susceptibility of MS.
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In a recent study. a connection was found regarding the genes responsible for the
production of the major histocompatibility complex cells that permeate the blood brain
barrier and are believed to be a major cause of the neurological damage seen in MS
(I Iaflcr. Compston et al. 2007). The HLA DR and HLA DQ class II genes, specifically
the class II ORB 1* 1501-DQA1 *0 102-DQB 1*0602 haplotype on chromosome 6p21, are
thought to give individuals a predisposition to the disease (Barcellos, Oksenberg et al.
2002). Recent studies have shown the locus association is more in the HLA DR Class II
region than in the l-ILA DQ region. The class TI region is responsi ble for encoding for the
antigen-presenting proteins located on the outside of the cell for recognition by T cells.
Other gene-association studies have shown linkage on chromosomes 5q33. 17q23 , and
19p 13. Polymorph isms of the cytokine interferon-gamma and apol ipoprotein E are
thought to be a part of the autosoma l yet gender-specifi c cause of mul tiple sc lerosis
(Kantarci and Wingerchuk 2006).
Environmental factors are also thought to play a role in the etiology of multiple
sclerosis. Geographical association for the disease is one type of evidence supporting this
cause ofMS. Multiple sclerosis is rare in Asia and is more common as latitude increases.
Also. MS is hardly found in tropical regions. An infectious agent. such as a type of
bacteria or viru s, has long been hypothesized to be a main cause of multiple sc lerosis.
There are three hypotheses postulating how a common infectious agent causes multiple
sc lerosis. The first, the poliomyelitis hypothesis. states that an infant who catches the
virus early in infancy acquires protective immunity. However, if the virus is caught in
late adolescence or in adulthood it can be more harmful. The prevalence hypothesis
states that a virus found in areas where multiple sclerosis is prevalent causes the disease.
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The poliomyelitic hypothesis has developed recently into the " hygiene" hypothesis, which
postul ates that exposure to many infectious agents can increase the li kelihood of an
individ ual getting MS. So me in fec ti o us agents tho ught to increase the risk of MS are the
Epstein-Barr Virus, Chlamydia pneumoniae, and the Human Herpes Virus 6. There have
been more consistent findings with studies done o n the E pstein-Barr V irus. Persons with
a histo ry of infecti ous m ono nucleosis, w hich is caused by the Epstein-Barr Vi rus, are
mo re likely to have MS than indiv iduals without a history of the virus. Recent stud ies on

Chlamydia pneumoniae show that exposure to this infectious agent might not increase the
risk o f the disease because its DNA was not found in the cerebrospinal fl uid in victims of
multiple sclerosis. The Iluman Herpes Virus 6 is still thought to increase the risk of the
disease because it was fo und in MS lesio ns in the brain in MS patients after death
(Ascherio and Munger 2007).
Other enviro nmental influences that are tho ught to increase an ind ividual's
chances of having multiple sc lerosis are lower levels of sunli ght ex posure and insufficient
vitamin D intake. Studies have shown that indi viduals w ho li ve in areas with higher
sunlight or have outdoor occupations are less likely to be diagnosed w ith multiple
sclerosis (Freedman, Dosemeci et al. 2000). Decreased ri sk of having MS due to
increased sunlig ht is expected to correlate with the finding that vi tamin D deficiency
increases the risk of multiple sclerosis. The UVB radiation fro m sunlig ht exposure leads
to the photosynthesis of vitamin D from its pre-acti ve form previtan1in 0 3 to its active
form vitamin D 3 . Vitamin Dis tho ught to have these effects o n autoimmune disorders
because hi gh levels ofvitamin D arc needed for the max imum secretion of the ho rmone
I ,25(0Il h D, which is a very effective modulator o f the immune system ( Holick 2004).
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Another risk factor for multiple sclerosis is cigarette smoking. Experiments have
shown that heavy smokers are more likely to get MS than people who have never
smoked, and smoking may cause a worsening of symptoms in MS patients. Also,
smoking has been shown to speed the changeover from the relapsing-remitting to
secondary-progressive MS (Ascherio and Munger 2007).
Research on the effects of sex hormones such as estrogen and progesterone on
multiple sclerosis was increased when studies showed that the MS attacks decreased
during pregnancy, most significantly during the third trimester when estrogen and
progesterone arc at their maximums. Estrogen has been shown to increase immune
system responses at low concentrations, but decrease immune system responses at high
concentrations. Sex hormones have the ability to affect the immune system by activating
certain lymphocytes and controlling the type of antigens presented on certain cells.
Based on these discoveries, sex hormones arc thought to play a role in the susceptibility
of people for multiple sclerosis (Whitacre 2001 ).

Treatments forMS
Although no cure forMS has been found, many treatment options have shown
positi\'C results for slowing the progression of the disease and providing neuroprotection
during the attacks associated with multiple sclerosis. There arc different treatment
options for people with the relapsing form and the progressive form of the disease.
(Staff2006).
Beta interferons are currently being used as a treatment option for patients with
relapsing-remitting MS. Interferon-beta 1-

~and

interferon-beta 1-

<X

are man-made

proteins identical to naturally occurring proteins in the body that function in modulating

8

the immune system and aid in fighting viral infections. The interferon beta 1-

~drug

available is called Betaseron. The interferon 1- ex drugs available are called A vonex and
Rebif. Betaseron and Rebifare taken subcutaneously. whereas Avonex is taken
intramuscularly. The beta interferon drugs have been shown to decrease the immune
activity ofMS, resulting in a reduction in the number of relapses (Flechter, Vardi et al.
2002). Beta interferon drugs are prescribed for ambulatory MS patients who experience
multiple flare-ups in a years· time. These drugs do not repair any damage that occurred
prior to taking the drug. Many patients have problems with the flu-like side effects
no rmall y fe lt while taking the drugs. In some patients. beta interferon drugs cannot be
administered due to their decreased efficacy or if the drug is harmful to their immune
system. Also, some patients develop antibod ies to the beta interferon drugs and are
unable to continue taking them. Therefore, drugs such as glatiramer acetate provide
another treatment option in MS patients (Staff2006).
Glatiramer acetate (Copaxone) is also a synthetic protein modeled after the amino
acid motifs of the myelin basic protein. Glatiramer acetate is helpful to multiple sclerosis
patients by providing the same benefits as the beta interferon drugs, namely retard ing the
progression of the disease and the number of flare-ups as well as decreasing the activity
in the lesions associated with the disease (Debouverie, Moreau et al. 2007). Glatiramer
acetate works by drawing helper T cells to si tes of inflammation, where they arc activated
and release \'arious cytokincs such as intcrleukin-(JL)-4, II.-5. and IL-1 3 that act to
protect the central nervous system. These cells have also been found to release a brainderived neurotrophic factor that may help repair neurons previously damaged by multiple
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sclerosis. Copaxone is injected subcutaneously once every day (Neuhaus, Farina et al.
2001).
Interferon beta and glatiramer acetate have been approved and are the first-line
agents prescribed by physicians. However, if these two drugs cannot be tolerated or are
not helpful to patients, Natalizumab may be prescribed to patients with aggressive,
relapsing MS. Natalizumab is injected intravenously once a day and has been shown to
decrease the number of exacerbations in MS patients by reducing the inflammatory
response in the central nervous system, thus not allowing the immune cells to cross the
blood brain barrier. However, this drug is normally prescribed only toMS patients for
whom no other treatment option has been successful due to the finding during a clinical
trial that some patients developed a potentially fatal disease called progressive multifocal
leukoencephalopathy (Rudick, Stuart et al. 2006).
Mitoxantrone, a drug normally prescribed for cancer patients, is an
immunosuppressive drug targeting immune cells such as T and B cells and macrophages.
Mitoxantrone has been shown to slow down the progression of MS, specifically the
demyelination associated with the disease. Mitoxantrone is prescribed forMS patients
with relapsing-remitting, secondary progressive MS, or progressive-relapsing MS and is
taken intravenously every three months. Many doctors refrain from prescribing this drug
due to its possibly serious adverse side effects, such as leukemias or cardiotoxicity, if
taken too long. Therefore, mitoxantrone is taken for a maximum of three years to
decrease the risk of a patient experiencing these side effects. The MS patient taking the
drug must be monitored closely to see if the correct dosage is being taken and to assess
the risks and benefits of the drug (Rizvi, Zwibel et al. 2004).
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A doctor may prescribe other medications to help relieve some of the symptoms
of multiple sclerosis. To help with muscle pains from tonic spasms due toMS , a doctor
may prescri be antispastic agents such as baclofcn or tizanidinc (Pollmann and Feneberg
2008). ror improvements in fatigue related to multiple sclerosis. amantidinc
hydrochloride has been shown to help increase energy, concentration, and problemso lving (Cohen and Fisher I 989). Some MS patients take physical and occupational
therapy to help strengthen their bodies and become adjusted to living with the disease.

Resveratrol
Resveratrol (lrans-3,5,4'-trihydroxystilbene) is a polyphenolic compound that
may be the new "wonder drug" due to its many potential beneficial properties concerning
the treatment of diseases. Resveratrol, found in mulberries, peanuts, and red grapes. is
used by plants as an antibiotic compound to fight fungal infection. Recently resveratrol
has been found to have anticancer, antioxidant, and anti-inflammatory properties.
Therefore, resveratrol could be used as a treatment option for multiple sclerosis due to its
abi lity to decrease inflammation. Experimental auto immune encephaliti s. or E/\E, is an
inflammatory disease commonly used in studies of multiple sclerosis due to its many
similariti es to the disease (Imam and Kuntze! I 977). Studies of resveratrol on EAEinduced mice showed that the compound lowered the secretion of several cytokines and
chemokincs such as interlcukin (IL)-2, IL-9 , IL- I 2, IL-17, tum or necrosis factor-n,
interferon-/ . macrophage inflammatory protein-! o. (MIP-1 a), and monocyte
chemoattractant protein- I (MCP-1 ). Many of these cytokines and chemokines are
believed to be pro-inflammatory mediators (Singh. I Iegde et al. 2007). One of the
possible ways resveratrol works is by suppressing the inflammatory response through the

1I

release of pro-inflammatory mediators and its ability to inhibit the synthesis of these
mediators through its effects on nuclear factor kB (NF-kB) or activator protein (AP-1).
N uclear factor kB is responsible for the increased expression of inducible nitric oxide
synthase (iNOS) and cyclooxygenase-2 (COX-2). Nitric oxide and cyclooxygenase are
enzyme systems responsible for the synthesis of many pro-inflammatory mediators in the
body. Nuclear factor kB is a transcription factor for genes involved in inflammation,
whereas AP-1 is a transcription factor for genes involved in cell differentiation (de Ia
Lastra and Villegas 2005).

Neuropro tection
Beta-interferon and glutiramer acetate treatments are available for slowing the
progression of multiple sclerosis, but there are not any drugs available that have shown
conclusive ability to provide neuron protection. A drug with neuroprotective properties
could protect the neurons from damage during an exacerbation of MS resulting in the
disappearance of the symptoms associated with the disease. Although more studies on
the neuroprotective effects of resveratrol should be performed, resveratrol seems to
protect neurons from damage in cerebral ischemia by raising the nitric oxide level and
lowering the hydroxyl radical level. Though this finding may seem contradictory due to
information previously stated about raising the nitric oxide level leading to harmful
effects in MS, the higher nitric oxide level is helpful because nitric oxide is a vasodilator.
Therefore, nitric oxide causes an increase in blood flow that is crucial in the event of a
stroke (Lu, Chiou et al. 2006)
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Neuroblastomas as J\1odelfor Neurons in Multiple Sclerosis
Fully developed neurons are no longer capable of dividing. Therefore, using
neurons in the studies of multiple sclerosis is impractical and presents many problems for
researchers studying autoimmune diseases such as multiple sclerosis. Neuroblastoma
cells are sometimes used in studies of MS because these cancer cells are constantly
dividing and exhibit similar properties to the fully developed neurons of the central
nervous system that are damaged in the attacks of multiple sclerosis. Neuroblastoma is a
chi ldhood cancer of the sympathetic nervous system and is ideal for cell models for its
ability to go through chemically induced cell differentiation (Abemayor and Sidell 1989).

Methods

Cell Culture
HAPi microglia cells \Vere cultured at 3TC and 5.0% C02 in Dulbecco's
Modification of Eagle's Medium with Earle's salts containing a final concentration of
I 0% fetal bovine serum and 1.38 mM L-glutamine.

Primary Cell Culture
Primary mouse microglia cultures were obtained through a modification of the
McCarthy and de Vellis protocol. Cerebral cortices from 1- to 3-day-old C57BL/6 mice
were excised, meninges removed, and cortices minced into small pieces. Cells were
separated by trypsinization followed by trituration of cortical tissue. The cell suspension
vvas filtered through a

70-~m

cell strainer to remove debris. Cells were centrifuged at

153 xg for 5 min at 4°C; resuspended in DMEM medium containing 10% FBS , 1.4 mM !glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, OPl medium supplement, and
0.5 ng/mL recombinant mouse GM-CSF; and plated into tissue-culture flasks. Cells were
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allowed to grow to confluence (7- 10 days) at 37°C/5% C02. Flasks were then shaken
overnight (200 rpm at 37°C) in a temperature-controlled shaker to loosen microglia and
oli godendrocytes from the more adherent astrocytes. These less-adherent cells were
plated for 2-3 hr and then lightly shaken to separate oligodcndrocytes from the moreadherent microglia. Microglia were seeded in 96-well plates (4

x

4

10 cells/ well) and

incubated overnight at 37°C/ 5% C02. Astrocytes were recovered by trypsinization and
seeded into 96-\\ell plates (I x I 0 5 cells/well).

Determination ofCel/ Viablility
An MTT (3-(4,5-dimethylthiazone-2yl)-2,5 -diphenyltetrazo lium bromide) assay
measuring mitochondrial activity was used to assess cell viability. MTT solution was
prepared by diluting MTT I :50 with culture medium. Cell culture media were removed
from cells and replaced with 500 J.!L MTT solution and incubated at 37

·c for 1 hr. MTT

sol ution was removed and cells were lysed by adding 500 J.!L DMSO/wcll. Plates were
rocked for 30 min and read on a plate reader at 570 nm.

Determination ofNitrite Production
Ce lls were plated in a 24-well plate at 2.5 x 105 cells/well and incubated for 24 hr
before treatment with RES. Cells were then incubated 4 hr before inducing activation of
I IAPi microglial cell s with LPS. Media was harvested from wells after 24 hr; 50 J.!L of

each sample were added to a 96-well plate with 50 J.!L Gries reagent and read on a plate
reader at 550 nm.
/L-6 Elisa Assay

JL-6 production by microglia was determined according to manufactcrcr' s
reco mmendations (BD Biosciences-PharMingen, San Diego, CA). For analysis of IL-6,
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microwells were coated with I OO~tL per well of Capture Antibody diluted in Coating
Buffer. The plate was sealed and incubated overnight at 4° C. The wells were aspirated
and washed three times with 300
\\-ith 200

~L/wcll

~L/well

of wash buffer. The plates were then blocked

of Assay Diluent. The plate was then incubated at room temperature

for I hr. The wells were again aspirated and washed three times with JOOuL/well of
wash buffer. Standard and sample dilutions in Assay Diluent were prepared. I OOuL of
each standard, sample, and control were pipetted into appropriate wells. The plate was
sealed and incubated for 2 hrs at room temperature. The wells were again aspirated and
washed, but with a total of five washes. I OO~L of Working Detector (Detection
Antibody + SA\-1 IRP reagent) were added to each \\-ell, and the plate was sealed and
incubated for l hr at room temperature. The wells were then washed again, but with
seven total washes. I OO~tL of Substrate Solution were then added to each well. Then, the
plate was left to incubate unsealed in the dark for 30 min. at room temperature. 50

~L

of

Stop Solution were added to each well. The absorbance was read at 450nm within 30
min. of stopping the reaction.
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FIG I . Rcsver a trol d ocs not affect t he v iabili ty of H APi mi crogli a l cells indu ced by

LPS.
Cells were pre-treated for 1 hr with the ind icated concentrati ons of RES. LP S was added
at 0.5 mg/mL and 24 hr later cell viability was determined. Values represent the average
for tripli cate cultures. Standard errors are indicated. No stati sticall y significant
differences in viabi lity between samples were observed.
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FIG 2. Resveratrol inhibits LPS induction of nitrite in HAPI microglia cells.
Cells were pre-treated for I hr with the indicated concentrations of RES. LPS was added
at 0.5 mg/mL and 24 hr later the concentration of nitrite in the cu lture media was
determined. Values represent the average for triplicate cultures. Standard errors are
indicated. Comparisons were made to LPS-onl y treated cultures. Asterisks indicate
sta ti stical significance of p < .05.
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FIG 3. Resveratrol inhibits LPS induction of Il-6 in HAPI microglia cells. Cells
were pre-treated fo r 1 hr with the indicated concentratio ns of RES. LPS was added at 0.5
mg/mL and 24 hr later the concentration o f IL-6 in the culture media was determined.
Values re present the average for triplicate cultures. Standard errors are indicated.
Compari sons were made to LPS-only treated cultures. Asteri sks indicate stati sti cal
s ignificance of p < .05.
Simi lar data were observed for IL- 12p40, TNF-a, M CP- 1, and lL-lB (in primary
microglia).
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FIG 4. IFN-y/TNF-a. cocktails and Ge02 can induce apoptosis in neuro-2a
neuroblastoma cells. IFN-y/TNF-a. or Ge0 2 was added to culture medium at indi cated
concentrations and 72 hr later cell viability was determined. Values represent the average
for triplicate cultures. Standard errors are indicated. Asterisks indicate statistical
sig nificance of p < .05 as compared to untreated samples. Altho ugh these apoptosis
agents initially showed pro mise in our system, they did not consistentl y and reproducibly
induce death in our neuro-2a ce lls.
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FIG 5. Resveratrol can induce apoptosis in neuro-2a neuroblastoma cells. Cells were
pre-treated with the indicated concentrations of resveratrol for 1 hr. Ge02 was added to
culture medium at indicated concentrations and 72 hr later cell viability was determined.
Values represent the average for triplicate cultures. Standard errors are indicated .
Asterisks indicate statistical significance of p < .05 as compared to untreated samples.
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Discussion

Resveratrol , a phytoestrogen found in the skins of several plants such as grapes
and mulberries, could be beneficial in the treatment of multiple diseases due to its
ph~siological

effects. which include the extension of one's lifespan, cancer prevention,

and, of main concern in our research, anti-inflammatory properties (Singh, I Iegde et al.
2007). The damage resulting from multiple sclerosis, an autoimmune disease affecting
the central nervous system, is believed to be caused by the release of certain
inJlammatory cytokincs such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-a),
interleukin-12 p40 (IL-12 p40), interleukin-1 P(IL-1 p), and interleukin-6 (IL-6) which
attack the myelin sheath. These cytokincs have been found in the MS lesions in
indi'l-iduals v.ith multiple sclerosis and arc produced by activated astrocytes or microglia.
These cytokines have been linked to this disease for their ability to modulate
inflammation and demyelination (Benveniste 1997).
Though many treatments for multiple sclerosis are available, no drug is avai lable
that can suppress the cytokines which cause the inflammation while providing
neuroprotection. Therefore, our research was centered on discovering resveratrol' s
effects on \'arious cytokines linked to multiple sclerosis and its ability to pro\'idc
protection to the neurons in the central nervous system attacked during an exacerbation of

MS.
Our results indicate that resveratrol significantly inhibits LPS induced production
of nitrite in HAPi microglial cells. To ensure that the nitrite inhibition was not caused by
the compound's effect on the viability of the cell. an MTT assay was performed. The
MTT assay showed that resveratrol docs not affect IIAPi microglial viability. Therefore,
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resveratrol could suppress nitrite without killing the microglia, resulting in decreased
neurodegeneration and a lightening of the symptoms associated with MS. Resveratrol
\·\ as also found to suppress the pro-inflammatory cytokines IL-6, IL-l2p40, TNF-a,
MCP-1, and IL- lB (in primary microglia), therefore indicating resveratrol is a global
suppressor of inflammatory cytokines. IL-l B is isolated from primary microglia because,
after being genetically modified to divide repeatedly for its use in the lab, the HAPi cells
are not able to produce this speci fie cytokine.
ln our experiments to determine whether resveratrol provides neuroprotection,
initially inducing apoptosis in the neuroblastoma cells was more arduous than had been
anticipated. Ilowever, we found literature showing the ability of Ge02 to induce
apoptosis in neuro-2a neuroblastoma cells. This finding did not prove to be consistent
with our research. We also felt Ge02 was too artificial a system considering that it is a
metal and not likely to be used in treatment of individual s with MS. To more closely
mimic the actual environment of MS, we tried varying concentrations of IFN -y and TNFa. These human cytokines showed promise as well, but the results were also
inconsistent. Surprisingly, in our attempts to show protection by resveratrol from
apoptosis, our MIT data actually showed dose-dependent induction of apoptosis and the
addition of resveratrol to Ge0 2 treated cells enhanced apoptosis. Therefore, resveratrol 's
abi lity to provide neuroprotection could not be tested due to its anti-cancer ability to kill
the neuroblastomas used in our experiments. Using these findings, our lab plans to test
the effects of resveratrol on Ewing's sarcoma cells. another neural-derived tumor with
poor prognosis, in hopes of finding a new treatment for cancer.
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